Cite
HARVARD Citation
Gastaldelli, A. et al. (2020). Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes, obesity & metabolism. 22 (3), pp. 393-403. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Gastaldelli, A. et al. (2020). Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes, obesity & metabolism. 22 (3), pp. 393-403. [Online].